Arch Ophthalmol. 1997 Dec;115(12):1545-52.
To assess the 5-year visual course, including the incidence of recurrent optic neuritis, in 454 patients enrolled in the Optic Neuritis Treatment Trial.
Five-year follow-up vision testing, which included measures of visual acuity, contrast sensitivity, visual field, and color vision, was completed for 397 (87%) of the 454 patients.
Visual function test results in the eyes that experienced optic neuritis at study enrollment (affected eyes) were normal or only slightly abnormal after 5 years in most patients; the results did not significantly differ by treatment group (P=.37 for visual acuity). The visual acuity in the affected eyes was 20/25 or better in 87%, 20/25 to 20/40 in 7%, 20/50 to 20/190 in 3%, and 20/200 or worse in 3%. The recurrence of optic neuritis in either eye occurred in 28% of the patients and was more frequent in patients with multiple sclerosis (P=.001) and in patients without multiple sclerosis who were in the prednisone treatment group (P=.004). Most eyes with a recurrence retained normal or almost normal visual function.
Most patients retained good to excellent vision in the 5 years following an attack of optic neuritis, even if the optic neuritis recurred. Recurrences were more frequent in patients with multiple sclerosis and in those treated with oral prednisone alone. The completion of the 5-year follow-up by the Optic Neuritis Treatment Trial cohort has not altered our management recommendations based on the results we reported earlier.
评估参与视神经炎治疗试验的454例患者的5年视力变化过程,包括复发性视神经炎的发生率。
对454例患者中的397例(87%)完成了为期5年的随访视力测试,其中包括视力、对比敏感度、视野和色觉测量。
在大多数患者中,研究入组时发生视神经炎的眼(患眼)在5年后视觉功能测试结果正常或仅轻微异常;各治疗组结果无显著差异(视力P = 0.37)。患眼视力在87%的患者中为20/25或更好,7%的患者为20/25至20/40,3%的患者为20/50至20/190,3%的患者为20/200或更差。28%的患者出现任一眼视神经炎复发,在多发性硬化患者(P = 0.001)以及未患多发性硬化但接受泼尼松治疗组的患者中更常见(P = 0.004)。大多数复发眼仍保持正常或几乎正常的视觉功能。
大多数患者在视神经炎发作后的5年中保持良好至极佳的视力,即使视神经炎复发。多发性硬化患者和仅接受口服泼尼松治疗的患者复发更频繁。视神经炎治疗试验队列完成的5年随访未改变我们基于早期报告结果提出的管理建议。